Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Short-Term Debt issuances came in at $12.4 billion in Q1 2026, up 41.61% year-on-year from $8.8 billion in Q1 2025, and up 217.89% quarter-over-quarter from $3.9 billion in Q4 2025.

Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Short-Term Debt issuances across 18 years of filings, most recently posting $12.4 billion for Q1 2026.

  • Short-Term Debt issuances for Q1 2026 came in at $12.4 billion, up 41.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.2 billion (down 2.96% YoY), and the FY2025 annual result was $14.6 billion, down 4.52% from the prior year.
  • Short-Term Debt issuances came in at $12.4 billion for Q1 2026 at Johnson & Johnson, up from $3.9 billion in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $14.9 billion in Q1 2023 to a low of -$2.0 billion in Q3 2024.
  • The 5-year median for Short-Term Debt issuances is $3.3 billion (2024), against an average of $4.9 billion.
  • Across the five-year window, Short-Term Debt issuances surged 13026.09% in 2022 and sank 926.56% in 2024, its largest moves.
  • Johnson & Johnson's Short-Term Debt issuances stood at $3.0 billion in 2022, then sank by 57.57% to $1.3 billion in 2023, then surged by 157.06% to $3.3 billion in 2024, then gained by 18.83% to $3.9 billion in 2025, then soared by 217.89% to $12.4 billion in 2026.
  • The last three Short-Term Debt issuances figures came in at $12.4 billion (Q1 2026), $3.9 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Issuance (Qtr)
1 Gsk 92,134,969.93 Bn 92,134,964.97 Bn 7.76 Bn 1.61 Bn
2 Eli Lilly 1,027.45 Bn 1,022.17 Bn 16.22 Bn 1.78 Bn
3 Johnson & Johnson 559.08 Bn 537.03 Bn 15.96 Bn 12.44 Bn
4 AbbVie 394.75 Bn 385.40 Bn 10.78 Bn -499.00 Mn
5 Merck 295.12 Bn 289.47 Bn 12.09 Bn 1.06 Bn
6 Amgen 186.65 Bn 174.61 Bn 5.87 Bn -
7 Gilead Sciences 159.22 Bn 151.50 Bn 5.52 Bn -
8 Pfizer 146.00 Bn 133.23 Bn -1.21 Bn -127.00 Mn
9 Bristol Myers Squibb 113.22 Bn 102.77 Bn 8.07 Bn 321.00 Mn
10 Novartis Ag 108.02 Bn 107.33 Bn - 747.00 Mn

Historic Data

Download Data
DateValue
Mar 29, 2026 12.44 Bn
Mar 29, 2026 12.44 Bn
Dec 28, 2025 3.91 Bn
Dec 28, 2025 3.91 Bn
Sep 28, 2025 1.32 Bn
Sep 28, 2025 1.32 Bn
Jun 29, 2025 565.00 Mn
Jun 29, 2025 565.00 Mn
Mar 30, 2025 8.78 Bn
Mar 30, 2025 8.78 Bn
Dec 29, 2024 3.29 Bn
Dec 29, 2024 3.29 Bn
Sep 29, 2024 -1.99 Bn
Sep 29, 2024 -1.99 Bn
Jun 30, 2024 8.71 Bn
Jun 30, 2024 8.71 Bn
Mar 31, 2024 5.26 Bn
Mar 31, 2024 5.26 Bn
Dec 31, 2023 1.28 Bn
Dec 31, 2023 1.28 Bn